ArticleLa Radiologia medica2025
Efficacy and safety of transarterial chemoperfusion for head and neck malignancies.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate tumor response and overall survival (OS) of patients with head and neck malignancies treated by transarterial chemoperfusion (TACP). MATERIALS AND
methodsThis monocentric retrospective study included a total of 77 patients with head and neck malignancies, who were at least treated by one session of TACP in palliative-intent between 2002 and 2021. Tumor response to therapy was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Local control was defined as achieving either partial response (PR) or stable disease (SD).
resultsAll 77 enrolled patients (mean age: 59 ± 12 years; 52 males) were analyzed according to OS. RECIST was performed in 70 out of 77 patients since follow-up imaging was not available in 7 patients. No major complications were observed. Considering RECIST, PR was achieved in 48.57% and SD in 44.29% of the patients, resulting in a local control rate of 92.86%. A total of 5 patients showed progressive diseases at a rate of 7.14%. The median OS was 12.6 ± 1.5 months. Patients with T1-T3 tumors had significantly longer OS compared to patients with T4.
conclusionPalliative TACP has the potential to improve local tumor control and achieve remarkable survival outcomes for patients with head and neck area malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.